) was determined 8 weeks after BM transfer. Each dot corresponds to a mouse and the mean (horizontal bar) is indicated. (D) Characterization of the CD11b + cells of the lamina propria of the large intestine. Cell suspensions were prepared from the lamina propria of the large intestine and analyzed as in Figure S1A . As observed in the skin dermis, analysis of the expression of Ly-6C and MHCII identified CCR2 + cell subsets (P1, P2 and P3) and CCR2 -cell subsets (P4 and P5). Note that the P5 cells correspond to CX 3 CR 1 hi intestinal macrophages and were formerly denoted as P4 cells (Bain et al., 2013; Tamoutounour et al., 2012) . The percentages of cells found in each of the specified gates are indicated. (E) Analysis of P1 to P5 cells and of CD11b + DCs for CX 3 CR 1 , F4/80, lysozyme M and CD68 expression. Cells were sorted from steady-state dermis of CX 3 CR 1-EGFP (Jung et al., 2000) and lysozyme M-EGFP (Faust et al., 2000) reporter mice and of wild-type mice (F4/80 and CD68 staining). Data shown in B-E are representative of at least 3 independent experiments. hi monocytes using GeneSet Enrichment Analyses (GSEA). Related to Figure 3 . Signatures corresponding to the specified myeloid cell lineages were derived from analysis of public datasets as described in Supplemental Experimental Procedures. The "DC" signature regroups the signature corresponding to Ftl3-L-dependent conventional DCs ("DC") and a signature specific for the CD11b + DC subset ("DC.CD11b") (Miller et al., 2012) . The "/DC" signature is the anti-correlated signature of the "DC.CD11b" signature. The "Mo.II -" signature regroups the signature corresponding to MHCII -and MHCII int/-Ly-6C hi blood monocytes ("Mo.6C + II -" and "Mo.6C -II int/-") and to genes that are expressed at lower levels in MHCII + blood monocytes ("/Mo.II + ") as compared to the other cell types examined (Gautier et al., 2012) . The "Mo.II + " signature regroups the signature corresponding to MHCII + Ly-6C hi blood monocytes ("Mo.II + ") and to genes that are expressed at lower levels in MHCII -and MHCII int/-blood monocytes ("/Mo.II -" and "/Mo.II int/-") as compared to the other cell types examined. The "macrophage" signature corresponds to the transcriptomic fingerprint of tissue macrophages (Gautier et al., 2012) . The "MF.TR" signature regroups the transcriptomic fingerprints specific of yolk sac macrophages ("MF.YS"), of tissue-resident CD11b hi .Mo" signature corresponds to the anti-correlated "MF.TR" signature. Gene Set Enrichment Analysis (GSEA) was used to test whether these various signatures were preferentially expressed in each specified cell subsets (blood Ly-6C hi monocytes (Ly-6C hi Bl), dermal P1-P3 cells, dermal P4-P5 macrophages and dermal CD11b + DCs) as compared to the other ones. The dot area is proportional to the absolute value of the normalized enrichment score (NES), which varies from ~1 (no enrichment) to 5 (maximal enrichment). The color intensity of the dots represents the statistical significance of the enrichment. Hence, the bigger and darker the dots are, the stronger the enrichment of the signature is. The most remarkable enrichment patterns are highlighted in yellow. (A) Migratory moDCs expressed high levels of genes selectively expressed by P2 or P3 dermal moDCs as compared to P4 and P5 dermal macrophages. The "UP signature" includes the U1 to U5 GeneSets. U1 and U2 correspond to genes expressed to higher levels in monocyte-derived P1-P2-P3 cells and in P2 cells, respectively, as compared to P4-P5 macrophages and irrespective of DNFB treatment. U3 corresponds to genes expressed to higher levels in P2 cells from DNFBtreated mice than in P4-P5 macrophages. U4 and U5 correspond to genes expressed to higher levels in steady-state P2 and P3 moDCs, respectively, than in P4-P5 macrophages. The "DOWN signature" corresponds to genes expressed to lower levels in monocyte-derived P1-P2-P3 dermal cells as compared to P4-P5 macrophages and irrespective of DNFB treatment. Gene Set Enrichment Analysis (GSEA) was used to test whether the UP and DOWN signatures were preferentially expressed in the migratory moDCs found in the auricular LN of DNFB-treated ear as compared to steady-state dermal P2, P3, P4 and P5 cells and to P2 moDCs from DNFB-treated ear skin. (B) Convergence in the transcriptomic signatures of migratory CD11b + DCs and migratory moDCs. GeneSets corresponding to DC migration (M1 to M3) and DC activation (A1 to A2) were defined based on comparative gene expression profiling. M1 corresponds to genes expressed to higher levels in migratory CD11b
+ DC than in their dermal counterparts, irrespective of DNFB treatment. M2 corresponds to genes expressed to higher levels in migratory CD11b + DC than in their dermal counterparts following DNFB treatment. M3 corresponds to genes expressed to higher levels in migratory CD11b + DC than in their dermal counterparts under steady-state conditions. A1 corresponds to genes expressed to higher levels in DNFB-activated migratory dermal CD11b + DCs as compared to their steady-state counterparts. A2 corresponds to genes expressed to higher levels in DNFB-activated CD11b + dermal DCs as compared to their steady-state counterparts. A3 corresponds to genes expressed to higher levels in DNFB-activated P2 moDCs as compared to their steady-state counterparts. The DOWN GeneSet consist of the lists of genes that are anti-correlated to the UP GeneSet. GSEA was used to test whether the above GeneSets were preferentially expressed in migratory moDCs_DNFB, migratory CD11b + DCs_DNFB, migratory CD11b + DCs, and CD11b + dermal DCs_DNFB as compared to P2 cells_DNFB, CD11b + dermal DCs_DNFB, P2 dermal cells, P3 dermal cells and CD11b + dermal DCs. The genes contributing the most strongly to the enrichments highlighted by the boxes are illustrated as heatmaps in panels (E) and (F). (C) Heat map corresponding to signature of the dermal P1, P2 and P3 cells across the migratory moDCs found in the LNs of DNFB-treated ears, the monocyte-derived P1 to P3 cells found in steady-state and DNFB-treated skin, and the P4-P5 macrophages found in steady state-dermis. (D) Heat map corresponding to the signature of the P4-P5 dermal macrophages signature across the migratory moDCs found in the LNs of DNFB-treated ears, the monocyte-derived P1, P2 and P3 cells found in steady-state and DNFB-treated skin, and the P4-P5 macrophages found in steady state-dermis. (E) Heat map corresponding to the migration-activation UP signature across the CD11b + DCs found steady-state and DNFB-treated ears and their migratory counterparts, the monocytederived P1, P2 and P3 cells found in steady-state and DNFB-treated skin, and the migratory moDCs found in the LNs of DNFB-treated ears. (F) Heat map corresponding to the migration-activation DOWN signatures across the CD11b + DCs found steady-state and DNFB-treated ears and their migratory counterparts, the monocytederived P1 to P3 cells found in steady-state and DNFB-treated skin, and the migratory moDCs found in the LNs of DNFB-treated ears. + -type DCs and CD11b + -type DCs develop in the dermis in a Flt3L-dependent and CCR2-independent manner from blood-derived pre-DC precursors. These dermal DCs continuously migrate to the CLN in a CCR7-dependent manner. Second, a developmental series -originally identified in the LP of the intestine as the "monocyte-waterfall" (Bain et al., 2013; Tamoutounour et al., 2012) ). All the cells belonging to that monocyte series express CCR2. Rare dermal moDCs migrate to the skin-draining LNs under steady-state conditions. Third, the dermis contains P4 and P5 macrophages that can be readily distinguished from dermal monocytes by their lack of CCR2 expression and by the presence of high levels of CD64 and MerTK. P4 macrophages differ from P5 macrophages by the expression of low levels of MHCII and likely constitute the precursors of P5 macrophages. P4 and P5 macrophages are unique among dermal cells in that they expressed genes involved in tissue homeostasis. In young mice kept under SPF conditions, the dermal P4-P5 macrophages likely result from both embryonic and adult hematopoietic contributions. Note that the dermis also contains LCs that originate from the epidermis and are in transit to the skin-draining LNs. (B) Under inflammatory (DNFB-induced) conditions, several independent processes occur in parallel in the dermis. First, dermal DCs continue to develop and to efficiently migrate to the skin-draining LNs where they trigger DNFB-specific CD8 + and CD4 + T cells. Second, massive numbers of Ly-6C hi blood monocytes seed the inflamed dermis and give rise to extravascular P1 monocytes and P2 moDCs. Dermal moDCs likely contribute to the activation of skin tropic memory CD8 + T cells, independent of cognate antigen (Soudja et al., 2012) . A few dermal moDCs acquired CCR7-dependent, DC-like migratory properties and reached the skin-draining LNs where they induced DNFB-specific CD8 + and CD4 + T cells. Although the inflammatory conditions achieved during DNFB-mediated inflammation do not induce massive dermal moDC migration, it remains possible that some other inflammatory conditions can enhance the skin-draining LN-homing property of dermal moDCs. In addition, in some inflammatory settings or during infections by viral, bacterial, fungal, and parasitic agents, dermal monocytes are likely capable of differentiating into tumor necrosis factor (TNF) and inducible NO synthase (iNOS)-producing DCs that are called Tip-DCs or inflammatory moDCs and that show potent antimicrobial effector functions (Aldridge et al., 2009; Bain et al., 2013; Dominguez and Ardavin, 2010; Tamoutounour et al., 2012) . Third, inflammation was without effect on the numbers of dermal P4-P5 macrophages and their presence may contribute to the resolution of the inflammatory response. 
Supplemental Experimental Procedures
Antibodies for flow cytometry APC-Cy7-conjugated anti-NK1.1 (PK136), anti-CD3 (17A2), anti-Ly-6G (1A8), anti-CD19 (6D5), and APC or PE-conjugated anti-CD64 (X54-5/7.1) were from Biolegend. Biotinconjugated anti-Mouse-Mer (BAF591) and PE-conjugated anti-CCR2 (475301) were from R&D, PE-Cy7-conjugated anti-CD11c (N418), Alexa-700-conjugated anti-MHC Class II (I-A/I-E) (M5/114.15.2), PE-Cy5.5-conjugated anti-CD45.2 (104), APC-conjugated anti-CD45.1 (A20), PE-Cy5-conjugated anti-CD24 (M1/69), and PE-Cy5-conjugated anti-CD5 (53-7.3) were all from eBioscience. PE-or biotin-conjugated anti-CD103 (M290), FITCconjugated anti-Ly6C (AL21), Pacific-Blue-conjugated anti-CD4 (RM4-5), and biotinconjugated anti-CCR7 (4B12) were all from BD Pharmingen. PE-conjugated anti CD68 (FA-11) was from Serotec, and biotin-conjugated anti-F4/80 (BM8) was from BioLegend. Biotin conjugated antibodies were detected using streptavidin conjugated with PE-TexasRed (Invitrogen).
Preparation of T cells
OT-I CD8 + T cells, OT-II CD4 + T cells, and CD8 + and CD4 + T cells from auricular LNs of DNFB-sensitized mice were purified by magnetic separation using CD8-and CD4-T cell negative isolation kits (Dynal, Invitrogen). T cells were stained with CFSE (Molecular probes) as described (Henri et al., 2010) , or with 5 µM Cell Trace Violet (CTV, Invitrogen) for 20 min at 37° C and then washed.
T cell stimulation CFSE-labeled CD8
+ or CD4 + T cells (5 x 10 4 ) from auricular LNs of DNFB-sensitized mice were stimulated with migratory CD11b + DCs and moDCs (2.5 x 10 4 ) sorted from auricular LNs of DNFB-sensitized mice. After 60 h of culture, cells were further incubated for 6 h in the presence of PMA (5 ng/mL) and ionomycin (250 ng/mL). Monensin (Golgistop, BD Pharmingen) was added to the suspension for the last 5 h. Cells were stained for extracellular markers and then permeabilized with the Cytofix/Cytoperm kit (BD Biosciences). Intracellular cytokines were detected by staining with PECy7-conjugated anti-IFN-(XMG1.2) from BD Pharmingen. Proliferation was measured by flow cytometry as a loss of CFSE staining. CD11b + cell subtypes sorted from steady-state skin were incubated for 2.5 hr at 37°C with OVA (100 µg/ml), or the OVA 257-264 peptide (1.4 nM), and then washed. CTVlabeled OT-I CD8 + or OT-II CD4 + T cells (2.5 x 10 4 ) were stimulated with OVA-or OVA 257-
